Triple Drug Antihypertensive Single-Pill Combinations Added to WHO Essential Medicines List
核心洞察
Triple drug fixed-dose antihypertensive single-pill combinations have been included as WHO essential medicines for the treatment of essential hypertension (搜索) in adults.
The inclusion is supported by evidence from randomized controlled trials, including the QUARTET and TRIUMPH studies, demonstrating superior blood-pressure-lowering efficacy of low-dose combinations versus monotherapy or usual care.
Single-pill combinations improve medication adherence and blood pressure control compared with free-equivalent combination therapy, addressing a key barrier in hypertension (搜索) management.
Triple drug fixed-dose antihypertensive single-pill combinations have been added to the World Health Organization (WHO) Model List of Essential Medicines for the treatment of essential hypertension (搜索) in adults. The application, submitted by Satheesh and colleagues, reflects a growing body of evidence that low-dose combination therapy delivered in a single pill can improve blood pressure control while simplifying treatment regimens for patients worldwide.
The WHO inclusion is grounded in a substantial evidence base spanning multiple randomized controlled trials. The QUARTET trial, a phase 3, randomised, double-blind, active-controlled study, demonstrated that initial treatment with a single pill containing a quadruple combination of quarter doses of blood pressure medicines achieved superior blood pressure reduction compared with standard dose monotherapy in patients with hypertension (搜索). Similarly, the TRIUMPH trial, a randomized clinical trial conducted in Sri Lanka, found that fixed low-dose triple combination antihypertensive medication achieved better blood pressure control than usual care in patients with mild to moderate hypertension.
A pivotal international trial published in The Lancet evaluated a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide compared with dual combinations for the treatment of hypertension (搜索). This randomised, double-blind, active-controlled trial provided further evidence supporting the efficacy and safety of triple single-pill combinations. Additional supporting evidence includes the QUARTET USA randomized trial, which assessed a four-drug, quarter-dose treatment for hypertension, and a randomized clinical trial in Nigeria comparing low-dose triple-pill therapy with standard-care protocols.
The clinical rationale for single-pill combinations rests on their ability to address a central challenge in hypertension (搜索) management: medication adherence. A systematic review and meta-analysis by Parati and colleagues found that adherence to single-pill therapy was superior to free-equivalent combination therapy in hypertension. This adherence advantage translates into improved blood pressure control, as demonstrated across multiple trials and meta-analyses comparing triple versus dual combination blood pressure-lowering drug therapy.
The global burden of hypertension (搜索) underscores the significance of this decision. The NCD Risk Factors Collaboration, in a pooled analysis of 1,201 population-representative studies with 104 million participants, documented worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019. The WHO has characterized hypertension as a "silent killer" in its Global report on hypertension, emphasizing the urgent need for effective, accessible treatment strategies.
The inclusion of triple drug fixed-dose combinations on the Model List of Essential Medicines carries particular importance for low- and middle-income countries, where hypertension (搜索) control rates remain disproportionately low. A systematic analysis of population-based studies from 90 countries highlighted global disparities in hypertension prevalence and control. Standardized treatment protocols and single-pill combinations have been identified as key strategies to improve access to medicines and simplify hypertension care in these settings.
Beyond clinical efficacy, single-pill combinations offer potential economic advantages. Analyses have suggested that treating hypertension (搜索) with single pill combinations represents a simple strategy to save costs for patients and payers. Cost-effectiveness evaluations, including a within-trial and modelled economic evaluation of the TRIUMPH trial, have examined the financial implications of fixed-combination, low-dose, triple-pill antihypertensive medication compared with usual care.
The WHO decision aligns with broader efforts to integrate hypertension (搜索) management into primary health settings, including the HEARTS initiative and the World Heart Federation roadmap on single pill combination therapies. These initiatives emphasize standardized treatment protocols and simplified regimens as foundational elements of effective cardiovascular disease prevention at scale.